GHK-Cu Sourcing & Quality: Permeation Gaps, Concentration Myths & Regulatory Status

Summary

• The label name: Copper tripeptide-1. Palmitoyl tripeptide-1 and palmitoyl GHK are different molecules and are not interchangeable with it.

• Concentration: Almost never disclosed, and it matters more here than usual because the dose-response is biphasic rather than ascending.1

• Stability: Robust in water and at pH 4.5 to 7.4 even at 60 degrees Celsius, vulnerable to basic and oxidative conditions.2

• Color: The blue indicates a coordinated copper species. It does not identify which one, and says nothing about potency.3

• The question no label answers: Almost no peptide or copper crossed intact skin in a controlled permeation study using in vitro human skin models.4

• Research powders: No published human pharmacokinetic data by any route. The rodent systemic dosing work that reports immunosuppression used copper-free GHK, not the copper complex.5,6

Read This Before Comparing Products

Every quality question below is downstream of one unresolved fact. In a 2015 study measuring permeation across in vitro human skin models, 134 nanomoles of peptide crossed microneedle-treated skin over nine hours, while across intact skin the authors recorded that almost no peptide or copper permeated.4

Choosing between two serums on purity, concentration or price presumes that the molecule arrives somewhere. That premise has not been established for intact skin, and a 2025 pharmaceutics review describes the clinical literature on the marketed forms as showing a surprising absence of studies.7

What Am I Actually Buying?

One of three quite different things, and the differences are larger than the marketing suggests.

Why Concentration Matters More Here Than Elsewhere

Because with this molecule no published setting shows more being better, and the one mapped curve shows it being worse.

For most active ingredients, an undisclosed concentration is an annoyance and the reasonable default assumption is that higher is stronger. GHK-Cu breaks that assumption. Its dose response has been mapped once clearly, and three further observations in unrelated systems point the same way:

• Glycosaminoglycan synthesis, the one mapped curve: explicitly described as biphasic, with maximal stimulation between 10 to the minus 9 and 10 to the minus 8 molar and the rate returning progressively toward control at higher concentrations.1

• Collagen synthesis: beginning between 10 to the minus 12 and 10 to the minus 11 molar and maximizing at 10 to the minus 9 molar.9

• Culture systems in general: optimal activity for copper-free GHK reported between 10 and 200 nanograms per milliliter, which is a window rather than a floor.10

• In people, two concentrations only: in a randomized hair growth trial the 50 mg/ml arm produced a larger hair count increase than the 100 mg/ml arm. Two active arms cannot establish a curve, and the agent was a 5-aminolevulinic acid complex rather than GHK-Cu.11

A product advertising an unusually high copper peptide percentage is advertising a position on the dose-response curve that the published data do not favor. That is not a reason to seek out the weakest product available either. It is a reason to treat concentration claims as marketing rather than as evidence of strength.

What Do the Stability Data Actually Say?

Better than the folklore suggests in ordinary conditions, and genuinely vulnerable in specific ones.

A preformulation study designed to support topical delivery subjected GHK-Cu to stressed conditions and quantified it with a validated stability-indicating chromatographic method. The findings are worth carrying into a purchasing decision:2

• Stable where it counts: The peptide was stable in water and in buffers across pH 4.5 to 7.4 for at least two weeks at 60 degrees Celsius. The authors described this as surprising. Sixty degrees for two weeks is a harsh accelerated condition, and most cosmetic formulations sit inside that pH range.

• Vulnerable to alkaline and oxidative conditions: Susceptible to hydrolytic cleavage under basic and oxidative stressors, and to a lesser extent acidic stress, with first-order degradation profiles.

• Degradation products identified: Three, one of which was the constituent amino acid histidine.

• Carrier compatibility is not uniform: Compatible with Span 60-based niosomes but less stable in the presence of the negatively charged lipid dicetyl phosphate.

Encapsulation efficiency is also worth knowing if a product advertises liposomal delivery. A 2023 study preparing GHK-Cu-loaded liposomes reported encapsulation efficiency of 31.7 percent for cationic and 20.0 percent for anionic liposomes at the best-performing formulation.12 Liposomal on a label does not mean all of the material is encapsulated.

Is the Blue Color Meaningful?

Mildly, and only in one direction.

The blue is a property of copper coordinated to the peptide. A pH titration of the complex shows three optical transitions with apparent pKa values of 3.6, 9.2, and 11.4, and the species present at physiological pH forms at the lowest of those.3

So color indicates that a coordinated copper species is present. It does not establish that the species is GHK-Cu rather than another copper compound, nor how much is there, nor how much intact tripeptide, nor purity. An absent, faded, or unexpected color is more informative than a normal one, because it suggests something has gone wrong.

What Should I Ask a Supplier?

Questions that a serious supplier can answer, and that separate real information from atmosphere.

• Which molecule, precisely: Copper tripeptide-1, palmitoyl GHK, or copper-free GHK. These are not interchangeable, and evidence for one does not transfer to the others.

• What concentration, and why that one: A supplier who has read the dose-response literature will have a reason for their concentration. One who has not will treat higher as self-evidently better.

• What pH is the finished product held at: The stability data are pH dependent, and the stable window is known.2

• Certificate of analysis per lot: Identity and assay of the raw material, ideally with the analytical method stated, and whatever else was tested, such as contaminants, microbial limits, endotoxin or water content.

• What delivery claim is being made, and on what evidence: This is the question that matters most and the one least likely to receive a substantive answer.

A certificate of analysis answers what was tested about the material, which may be identity, assay, purity, contaminants or more. It does not answer delivery, and it does not answer clinical effect. The industry routinely uses an answer to the first as though it settled the other two.

What About Research Powders and Injection?

This is a materially different risk category from a cosmetic, and the evidence base is thinner than for topical use.

Lyophilized GHK-Cu sold as research material is not marketed as a finished cosmetic or as an approved drug, so it does not carry the labeling, claim and testing requirements attached to either category. What rules do apply depends on how a given product is formulated, labeled and marketed, and in which country. Three facts are relevant before anyone considers this route.

• No human pharmacokinetics have been published. The pharmacokinetic work amounts to a 1997 rat experiment, which dosed copper-free GHK rather than the copper complex. After a single intravenous dose, GHK was rapidly degraded to the dipeptide histidyl-lysine, which was itself eliminated rapidly. Nothing comparable exists for GHK-Cu.5

• Systemic rodent dosing carries documented immunosuppression, for the copper-free peptide. A 2002 study is titled directly, describing the tripeptide as a hepatotropic immunosuppressor, and reports that ten intraperitoneal injections of GHK across 1.5 to 450 mg per kilogram dose-dependently suppressed immune reactivity measured as both antibody-producing cell counts and delayed-type hypersensitivity. Whether the copper complex behaves the same way systemically has not been tested.6 A companion paper reports deteriorated serum biochemistry and dystrophic liver changes at the higher dose.13

• A plausible drug interaction has been described. GHK, again the copper-free peptide, interacts with the angiotensin II AT1 receptor in isolated rat hepatocytes, with its effects blocked by losartan.14 That receptor is the target of a widely prescribed class of blood pressure medication.

The topical literature is more reassuring, though thinner than it sounds. A 2016 study in cultured keratinocytes found GHK-Cu was not cytotoxic and did not raise irritation biomarkers, while copper chloride and copper acetate did. That is a cell model rather than a clinical safety test in people, and either way it says nothing about injection.15

How Does This Compare With the Compounded Peptides?

GHK-Cu is on a different track from the compounded injectables, but it is not outside the process, and there is a date on it.

GHK-Cu was not among the substances the FDA's Pharmacy Compounding Advisory Committee considered for the 503A Bulks List at its meeting on 23 and 24 July 2026. That meeting covered BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax and Epitalon, each in free base and acetate form.16

That absence is easy to misread. FDA's list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026, places GHK-Cu, except for injectable routes of administration, in Category 1, meaning under evaluation. The document records that the substance was removed from Category 1 on 22 April 2026 when the nominations were withdrawn, then added back after one nominator clarified on 5 May 2026 that it intended to withdraw only the injectable route. FDA states it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 regarding potential inclusion of GHK-Cu on the 503A bulks list.17

So the non-injectable form has a live nomination and a review date, while the injectable nomination was withdrawn and is not currently before the committee. That is a statement about what has been nominated, not a ruling on the injectable form. Neither fact says anything about whether the compound works. A substance under evaluation is a substance nobody has yet been required to prove anything about.

Sources

Seventeen sources. Claims that cannot be traced to a retrievable source are not repeated on this page.

1. Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51(13):1049-1056. PMID 1522753.

2. Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-L-histidyl-L-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016;21(2):152-160. PMID 25384620. doi.org/10.3109/10837450.2014.979944

3. Freedman JH, Pickart L, Weinstein B, Mims WB, Peisach J. Structure of the Glycyl-L-histidyl-L-lysine-copper(II) complex in solution. Biochemistry. 1982;21(19):4540-4544. PMID 6291585.

4. Li H, Low YS, Chong HP, Zin MT, Lee CY, Li B, Leolukman M, Kang L. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015;32(8):2678-2689. PMID 25690343. doi.org/10.1007/s11095-015-1652-z

5. Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. J Chromatogr B Biomed Sci Appl. 1997;692(1):37-42. PMID 9187381.

6. Smakhtin MY, Sever'yanova LA, Konoplya AI, Shveinov IA. Tripeptide Gly-His-Lys is a hepatotropic immunosuppressor. Bull Exp Biol Med. 2002;133(6):586-587. PMID 12447473. doi.org/10.1023/a:1020242127443

7. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2025;15:30071. Open access. PMID 39963574. pmc.ncbi.nlm.nih.gov/articles/PMC11830136

8. Choi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, Park KC. Stem cell recovering effect of copper-free GHK in skin. J Pept Sci. 2012;18(11):685-690. PMID 23019153. doi.org/10.1002/psc.2455

9. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. PMID 3169264.

10. Pickart L. The use of glycylhistidyllysine in culture systems. In Vitro. 1981;17(6):459-466. PMID 7021400.

11. Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol. 2016;28(4):438-443. Open access. PMID 27489425. pmc.ncbi.nlm.nih.gov/articles/PMC4969472

12. Dymek M, Olechowska K, Hąc-Wydro K, Sikora E. Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Pharmaceutics. 2023;15(10):2485. Open access. PMID 37896245. pmc.ncbi.nlm.nih.gov/articles/PMC10610410

13. Smakhtin MIu, Konoplia AI, Sever'ianova LA, Shveinov IA. Pharmacological correction of immuno-metabolic disorders with the peptide Gly-His-Lys in hepatic damage induced by tetrachloromethane. Patol Fiziol Eksp Ter. 2003;(2):19-21. Article in Russian; abstract consulted. PMID 12838768.

14. García-Sáinz JA, Olivares-Reyes JA. Glycyl-histidyl-lysine interacts with the angiotensin II AT1 receptor. Peptides. 1995;16(7):1203-1207. PMID 8545239.

15. Li H, Toh PZ, Tan JY, Zin MT, Lee CY, Li B, Leolukman M, Bao H, Kang L. Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Sci Rep. 2016;6:37664. Open access. PMID 27892491. pmc.ncbi.nlm.nih.gov/articles/PMC5124859

16. US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Agenda and evaluated uses. Docket FDA-2025-N-6895. Page content current as of 6 August 2026. fda.gov

17. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated 14 May 2026. Category 1 entry for GHK-Cu except injectable routes, and the stated intention to consult the Pharmacy Compounding Advisory Committee before the end of February 2027. fda.gov/media/94155/download

Not medical advice

GHK-Cu has no FDA approval for any medical indication. FDA's list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026, places GHK-Cu except injectable routes in Category 1, under evaluation, with an advisory committee review expected before the end of February 2027. No therapeutic dose has been established for any of the uses discussed here. Regulators outside the United States were not surveyed for this page. Consult a qualified healthcare provider before acting on anything here.